

# Product Information Sheet for NRH-21765

## Pooled Human Serum Sample, Pfizer/Pfizer/Moderna Vaccines (1.0 mL)

**Catalog No. NRH-21765**

**Lot No. 70054619**

**For research use only. Not for use in humans.**

### Contributor and Manufacturer:

Jack Stapleton, M.D., Director, Levitt Center for Viral Pathogenesis, Professor, Division of Infectious Diseases, Departments of Internal Medicine and Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA

### Product Description:

NRH-21765 consists of pooled human serum samples from vaccinees in Iowa who completed a Pfizer vaccination series followed by a Moderna booster. The antibody titer is 7,140 IU per milliliter.<sup>1,2</sup>

### Material Provided:

Each vial contains approximately 1.0 mL of pooled human serum sample.

### Packaging/Storage:

NRH-21765 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -60°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Pooled Human Serum Sample, Pfizer/Pfizer/Moderna Vaccines (1.0 mL), NRH-21765."

### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

### Disclaimers:

This product is not intended for human use.

Use of this product is subject to the terms and conditions of the Emergency Use Simple Letter Agreement (EUSLA) and the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any

warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### Use Restrictions:

SARS-CoV-2 materials provided by BEI Resources under the EUSLA are made available for any legitimate purpose, including commercial purposes as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any further transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA, documented as described above and you must notify BEI Resources of each subsequent transfer. Any new materials made by you that are not the original material or unmodified progeny are excluded from this requirement and you are free to share and commercialize those as your materials.

### References:

1. Stapleton, J., Personal Communication.
2. Xiang, J., et al. "Establishment of Human Post-Vaccination SARS-CoV-2 Standard Reference Sera." medRxiv 2022.01.24.22269773; doi: <https://doi.org/10.1101/2022.01.24.22269773>.

ATCC® is a trademark of the American Type Culture Collection.

